abstract |
Antibody formulations comprising a mixture of non-reducing sugars, anti-α4β7 antibodies and at least one amino acid are described. The disclosed formulations have improved stability, reduced aggregate formation, in which they can delay the degradation of the anti-α4β7 antibody or exhibit any combination thereof. The present invention further provides a safe dosing regimen for these antibody formulations that is easy to follow and results in a therapeutically effective amount of an anti-α4β7 antibody in vivo. |